Introduction
============

Epithelial ovarian cancer (EOC) is one of the important causes of cancer-related deaths in women worldwide [@B1]. Although curative surgical resection is regarded as the primary treatment modality for ovarian cancer, most ovarian cancers are diagnosed too late [@B2], and the majority of patients with advanced stage disease experience disease recurrence [@B3]. Considering the poor prognosis, a method for accurately predicting the prognosis of patients with EOC after curative surgical resection is necessary to improve patient survival [@B4].

In patients with EOC, prognosis is determined based on analysis of cancer-related risk factors. A wide variety of features of high-risk cancer, including size of the tumor, size of the residual tumor [@B2], stage of the cancer [@B5], lymph node status [@B6], histologic type [@B7], histologic grade [@B8], malignant ascites [@B9], and cancer antigen 125 (CA-125) levels [@B10] are considered essential for predicting cancer-specific survival.

The outcomes of treatments in ovarian cancer patients are determined also by host-related risk factors including performance status, age [@B11], white blood cell (WBC) [@B12] and neutrophil counts [@B13], hemoglobin concentration [@B12], platelet counts [@B12], serum albumin levels [@B14], the neutrophil-lymphocyte ratio (NLR) [@B15]-[@B17], and the platelet-lymphocyte ratio (PLR) [@B18], [@B19].

The lymphocyte-monocyte ratio (LMR) is calculated as the absolute count of lymphocytes (ALC) divided by the absolute count of monocytes (AMC), and it has been suggested to be associated with survival in patients with malignant lymphomas [@B20]-[@B22] and many solid tumors, including those of head and neck [@B23]-[@B25], breast [@B26], lung [@B27]-[@B29], gastrointestinal tract [@B30]-[@B37], and genitourinary system [@B38], [@B39] cancers. However, to the best of our knowledge, the prognostic value of the LMR in patients with EOC has never been reported. Therefore, the aim of this study was to assess the value of the preoperative LMR for predicting survival in patients with EOC.

Methods
=======

We retrospectively evaluated 234 patients who underwent primary debulking surgery for EOC at university hospitals between January 2006 and December 2013. Those who had been treated with radiotherapy or neoadjuvant chemotherapy were excluded from the study. Patients with coexisting cancers or prior cancers other than non-melanoma skin cancers within the previous 5 years were also excluded from the study. Moreover, patients were ineligible for inclusion into the study if they had a concurrent autoimmune disease, or had evidence of infection. The retrospective review of these records was approved by the institutional review board, and this study was conducted in accordance with the detailed enforcement regulations of Korea and the principles of the Declaration of Helsinki.

Data including information on patient demographics was collected for analysis. Clinicopathologic variables including age, International Federation of Gynecology and Obstetrics (FIGO) stage, histologic type, histologic grade, size of the residual tumor, malignant ascites, and CA-125 levels were obtained retrospectively from patient medical records. Every cytoreduction was principally aimed at maximal tumor resection without visible residual tumor. Standard surgical procedures included midline laparotomy, total extrafascial hysterectomy with bilateral salpingo-oophorectomy, pelvic and paraaortic lymph node dissection, peritonectomy, bowel resection, omentectomy, splenectomy, and partial resection of other affected visceral organs. Ascites was collected after the incision was made for cytologic evaluation. If technically achievable, all visible cancer was resected to achieve optimal tumor debulking (leaving residual tumor ≤ 1 cm in maximal tumor diameter) [@B40].

Histologic type classification was reviewed for consistency by a single pathologist. Subtypes included serous, mucinous, endometrioid, clear cell, and mixed cell tumors [@B17]. Laboratory measurements, including CBCs and biochemical profile analyses, were conducted prior to the surgical resection as part of the routine evaluation. If numerous CBCs prior to surgery were available, the one that was performed on the nearby date before the surgical resection was selected for analysis. We determined optimized LMR cutoff values for predicting survival outcomes using receiver operating characteristic (ROC) curve analysis; the best LMR cutoff value for both progression-free survival (PFS) and overall survival (OS) was 2.07. Patients were grouped according to the results of ROC curve analysis as follows: LMR-low (LMR ≤ 2.07) and LMR-high groups (LMR \> 2.07). Differences in cancer- and host-related risk factors including age, FIGO stage, histologic type, histologic grade, optimal debulking (OD), and serum CA-125 levels between the LMR-low and LMR-high groups were analyzed. Independent-samples *t*-tests were used to assess continuous variables, whereas independent-samples chi-squared tests were used to assess categorical variables.

Response to primary adjuvant chemotherapy was evaluated according to RECIST criteria or Gynecologic Cancer Intergroup CA-125 criteria [@B41], [@B42]. Complete response (CR) was defined as the disappearance of all tumors for at least 4 weeks with normalization of CA-125 levels.

We also evaluated the impact of LMR differences between groups on both PFS and OS. PFS was defined as the time from chemotherapy initiation to disease progression. OS was measured from the date of surgery until death from any cause. Median PFS and OS were estimated by using Kaplan-Meier analysis, and survival curves were compared using log-rank tests. The Cox proportional hazards model was used for univariate analysis. The variable that has been analysis in the univariate analysis includes age, histologic type, histologic grade, FIGO stage, OD, malignant ascites, CA-125 levels, serum albumin levels, WBC counts, absolute neutrophil count (ANC), ALC, AMC, hemoglobin concentration, platelet counts, NLR, PLR, an LMR.

To identify the most important prognostic factors for survival, the multivariate Cox proportional hazards model was used; variables with *P*-values \< 0.1 were selected for multivariate analysis. All presented *P*-values are two-sided, and statistical significance was declared at *P*\< 0.05. Data were analyzed using SPSS statistical software, version 18.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

The baseline characteristics of the patients are displayed in Table [1](#T1){ref-type="table"}. Serous adenocarcinoma was the most common subtype (56.4%), and histologic grade 3 was the most frequent grade (48.3%) in our cohort. Endometriosis was additionally present in 20 patients (12.4%). In total, 82 (35.0%), 15 (6.4%), 118 (50.4%), and 19 (8.1%) patients had stage I, II, III, and IV disease, respectively. OD was performed in 203 (86.8%) patients. Malignant ascites was observed in 124 patients (53.0%). Response assessments to primary adjuvant chemotherapy were available for 211 patients, and CR was achieved in 147 (69.7%) patients. The median serum level of CA-125 was 290 units/mL, and the median serum albumin level was 4.2 g/dL.

Regarding the stratification of patients according to the LMR, the LMR-low and LMR-high groups included 48 (20.5%) and 186 (79.5%) patients, respectively. To evaluate the relevance of the LMR, we assessed differences in the baseline characteristics of the patients according to the different LMR categories. Significant differences of mean between the LMR-low and LMR-high groups were found in the following continuous variables: age (*P*= 0.0341), serum CA-125 levels (*P*\< 0.0001), serum albumin levels (*P*\< 0.0001), WBC count (*P*\< 0.0001), ANC (*P*\< 0.0001), ALC (*P*\< 0.0001), AMC (*P*\< 0.0001), NLR (*P*\< 0.0001) and PLR (*P*\< 0.0001). Moreover, significant differences were found in categorical variables including FIGO stage (*P*\< 0.0001) and malignant ascites (*P*\< 0.0001), but not OD, histologic type, or tumor grade (Table [2](#T2){ref-type="table"}).

According to Kaplan-Meier analysis, the 5-year PFS rates in the LMR-low and LMR-high groups were 40.0 and 62.5% (*P*\< 0.0001), respectively, and the 5-year OS rates in the two groups were 42.2 and 67.2%, respectively (*P*\< 0.0001) (Fig. [1](#F1){ref-type="fig"}). On Kaplan-Meier analysis, the 5-year PFS rates in the lower (≤ 62 years) and higher (\> 62 years) age groups were 65.2 and 35.0% (*P*\< 0.0001), respectively, and the 5-year OS rates in these age groups were 69.6 and 39.9%, respectively (*P*\< 0.0001). In addition, the 5-year PFS rates in patients with stage I/II and III/IV disease were 86.9 and 37.3% (*P*\< 0.0001), respectively, and the 5-year OS rates in these two patient groups were 91.4 and 41.6%, respectively (*P*\< 0.0001). Finally, the 5-year PFS rates in the lower (≤ 110.1 units/mL) and higher (\> 110.1 units/mL) CA-125 groups were 85.2 and 43.0% (*P*\< 0.0001), respectively, and the 5-year OS rates in these two groups were 81.0 and 51.6%, respectively (*P*= 0.0013) (Fig. [2](#F2){ref-type="fig"}).

Univariate analysis for PFS identified a significant difference in several variables, including age (*P*= 0.0005), FIGO stage (*P*\< 0.0001), OD (*P*= 0.0268), malignant ascites (*P*= 0.0025), CA-125 levels (*P*\< 0.0001), serum albumin levels (*P*= 0.0023), ANC (*P*= 0.0061), ALC (*P*= 0.0027), hemoglobin concentration (*P*= 0.0099), platelet counts (*P*= 0.0338), NLR (*P*= 0.0005), PLR (*P*= 0.0042), and LMR (*P*= 0.0012). Using the multivariate approach for analysing survival time, we identified age (hazard ratio \[HR\] = 1.65, 95% confidence interval \[CI\] = 1.02-2.67, *P*= 0.0421), FIGO stage (HR = 3.32, 95% CI = 1.61-6.85, *P*= 0.0012), and CA-125 levels (HR = 2.28, 95% CI = 1.08-4.81, *P*= 0.0313) as the strongest prognostic factors (Table [3](#T3){ref-type="table"}).

Univariate analysis for OS identified a significant difference in the same variables found to be significant for PFS: age (*P*= 0.0002), FIGO stage (*P*\< 0.0001), OD (*P*= 0.0018), malignant ascites (*P*\< 0.0001), CA-125 levels (*P*= 0.0022), serum albumin levels (*P*= 0.0012), ANC (*P*= 0.0121), ALC (*P*= 0.0290), hemoglobin concentration (*P*= 0.0099), platelet counts (*P*= 0.0285), NLR (*P*= 0.0103), PLR (*P*= 0.0003), and LMR (*P*= 0.0008). Using the multivariate statistical analysis for OS, age (HR = 2.16, 95% CI = 1.24-3.76, *P*= 0.0064), FIGO stage (HR = 3.36, 95% CI = 1.52-7.47, *P*= 0.0029), and the LMR (HR = 0.53, 95% CI = 0.30-0.94, *P*= 0.0293) were identified as significant prognostic factors (Table [4](#T4){ref-type="table"}).

Discussion
==========

EOC is the most lethal gynecologic cancer and one of the major causes of cancer-related death in women worldwide [@B1]. Although curative surgical resection is the standard treatment for ovarian cancer, most ovarian cancers are diagnosed at an advanced stage because early-stage disease is often asymptomatic [@B2], [@B43]. In addition, the majority of patients with advanced disease experience disease recurrence at some point, resulting in poor survival rates [@B3]. Considering its poor prognosis, a method for accurately predicting prognosis after curative surgical resection for EOC is required for improving patient survival rates [@B4].

The association between inflammation and cancer was first described by Virchow in 1863 [@B44], and emerging evidence has highlighted the importance of chronic inflammation in the malignant transformation, promotion, and metastasis of cancer [@B45], [@B46]. Moreover, inflammatory mediators present in the tumor microenvironment have been found to correlate with chemoresistance in several types of tumors [@B47]. Pretreatment numbers of peripheral blood cells, including lymphocytes, monocytes, and neutrophils have been suggested to be a significant prognosticator in various types of malignancies.

Lymphocytes are considered to play important roles in defenses against cancer cells by inducing cytotoxic cell death and suppressing tumor cell proliferation and migration. It is well accepted that tumor-infiltrating lymphocytes establish a defense barrier against cancer dissemination [@B45], [@B48]. Decreased lymphocyte counts in the blood and tumor stroma lead to downregulation of the immune response against tumors [@B39]. Moreover, decreased lymphocyte counts in the blood has been identified as an independent prognostic factor for OS in various cancers [@B23], [@B49]. In the present work, ALC was a prognostic factor for both PFS and OS based on univariate analysis but not on multivariate analysis (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). When limited to OS for ovarian cancer, our results were compatible with previous findings [@B15], [@B17]. Inflammation can trigger the mobilization of monocytes from the bone marrow to the peripheral blood [@B50]. After recruitment into tumor tissue, monocytes can differentiate into tumor-associated macrophages [@B51], [@B52]. Monocytes in the peripheral blood may reflect the formation or presence of tumor-associated macrophages [@B27]. Moreover, pretreatment numbers of peripheral blood monocytes correlate with poor prognosis in patients with various types of cancers [@B28], [@B36]. In this study, AMC was not a prognostic variable for either PFS or OS (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}).

In recent years, several prognostic indicators derived from peripheral blood such as NLR and PLR have been widely investigated as useful prognostic markers in cancers. Despite inconsistent results, these markers reportedly have significant diagnostic and prognostic value in a wide variety of cancers. The NLR, the ratio of the ANC to the ALC, has been demonstrated to be a prognostic parameter for various malignancies. Concerning ovarian cancer, the NLR was shown to be associated with worse pathologic features such as advanced tumor stage [@B16]; an elevated NLR predicted poor PFS [@B16], [@B53] or OS [@B15]-[@B17]. In addition, an elevated PLR, a simple ratio between the platelet count and ALC, was associated with a higher rate of advanced disease among patients with ovarian cancer [@B18], and the impact of an elevated PLR on the survival of women with EOC has been demonstrated [@B18], [@B19]. In the present work, we also found a stage-dependent (stage I/II vs. III/IV) mean difference in both the preoperative NLR (2.99 vs. 5.12, *P*\< 0.0001) and PLR (175.03 vs. 297.23, *P*\< 0.0001). Although the prognostic impact of the NLR and PLR on PFS and OS was demonstrated by univariate analysis, the significance of the associations was lost on multivariate analysis (Table [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}).

The LMR, the ratio between the ALC and AMC, has been suggested to be associated with survival in patients with malignant lymphomas [@B20]-[@B22] and many solid tumors, such as head and neck [@B23]-[@B25], breast [@B26], lung [@B27]-[@B29], esophageal [@B30], [@B31], gastric [@B32], [@B33], colorectal [@B34], [@B35], pancreatic [@B36], [@B37], bladder [@B38], and cervical cancers [@B39]. The cutoff values for the LMR were determined by ROC curve analysis in most studies, and the value ranged from 2.6 to 5.1. A low LMR was associated with poor OS in previous reports [@B20], [@B21], [@B23], [@B25], [@B27]-[@B31], [@B34]-[@B39], and the LMR can be considered a potential surrogate biomarker in various cancers. Although the mechanisms of the association between lower LMR and poor prognosis have not been fully clarified, the LMR may reflect the balance between the favorable role of lymphocytes and the unfavorable effect of monocytes with respect to cancer progression [@B25]. The present study demonstrated that the LMR was a surrogate marker for OS, but not PFS on multivariate analysis (Table [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). The role of the LMR as a prognostic factor for OS, but not relapse- or disease-free survival, has been reported previously for other cancers such as gastric [@B32] and colorectal cancers [@B34]. In the present study, a significant difference was observed in the CR rate between the LMR-low and LMR-high groups (48.9% vs. 75.3%, *P*\< 0.0001). Tumors in patients with an elevated LMR tend to respond better to chemotherapy, and the result of this study was in line with that of previous research [@B26]. In the present work although the circulating ALC could predict survival outcomes, the LMR was shown to outperform the ALC, which is in line with a previous report [@B27].

The strength of the current study is that this was the first attempt to evaluate the prognostic value of the LMR in patients with EOC. Moreover, the value of the LMR was evaluated together with previously validated biomarkers, namely the NLR and PLR. In addition, our study was conducted at multiple institutions. Finally, it might be possible to identify patients who are at high risk of experiencing recurrence or death after the current standard treatment by performing simple and low-cost peripheral blood examinations.

This study had some limitations to be addressed, including its retrospective nature and the inclusion of a relatively small number of patients. Another limitation is that the LMR is a non-specific marker of inflammation, and the results may be affected by the presence of other systemic diseases [@B54]. To apply this convenient, simple, and inexpensive prognostic factor for risk stratification, additional large-scale and standard investigations should be conducted.

In conclusion, this study was the first attempt to assess the prognosis of ovarian cancer patients based on three biomarkers, the NLR, PLR, and LMR. In this study, we identified that an elevated LMR was strongly correlated with longer survival and was an independent prognostic factor for survival in patients with EOC, as determined by multivariate Cox proportional hazards model. Therefore, the LMR may be clinically reliable, and it can be used for accurate prediction of patient prognosis.
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###### 

Clinicopathologic characteristics of 234 patients with epithelial ovarian cancer

  Variable                     Median (range)           
  ---------------------------- ------------------------ ------------
  Age (years)                  54 (14-84)               
  Histology, *n* (%)                                    
                               Serous                   132 (56.4)
                               Mucinous                 35 (15.0)
                               Clear cell               35 (15.0)
                               Endometrioid             21 (10.0)
                               Mixed epithelial         5 (2.1)
                               Other                    6 (2.6)
  Histologic grade, *n* (%)                             
                               G1                       46 (19.7)
                               G2                       65 (27.8)
                               G3                       113 (48.3)
                               Not available            10 (4.3)
  Endometriosis, *n* (%)                                
                               Absence                  205 (87.6)
                               Presence                 29 (12.4)
  FIGO Stage, *n* (%)                                   
                               I-II                     97 (41.5)
                               III-IV                   137 (58.5)
  Optimal debulking, *n* (%)                            
                               No                       31 (13.2)
                               Yes                      203 (86.8)
  Malignant ascites, *n* (%)                            
                               No                       110 (47.0)
                               Yes                      124 (53.0)
  CA-125 (Unit/mL)             290 (5-17619)            
  Albumin (g/dL)               4.2 (1.8-5.3)            
  WBC (per µL)                 6790 (1530-18000)        
  ANC (per µL)                 4661.9 (981.2-15480.0)   
  ALC (per µL)                 1496.2 (212.7-5215.9)    
  AMC (per µL)                 426.0 (116.3-2003.4)     
  Hemoglobin (g/dL)            12.4 (5.2-15.6)          
  Platelet (× 10^3^/µL)        300 (104-1144)           

CA-125, cancer antigen 125; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count

###### 

Clinical and pathologic characteristics according to the lymphocyte-monocyte ratio (LMR) in 234 patients with epithelial ovarian cancer

  Variable                LMR-low (≤ 2.07)                 LMR-high (\> 2.07)         *P*-value                                
  ----------------------- ------------------ ------------- -------------------- ----- ------------- ----------------- -------- -----------
  Age (years)             48                 58.0 ± 12.5                        186   53.7 ± 12.7                     0.0341   
  Histology               Serous             33                                       99                                       0.0531
  Non-serous              15                 87                                                                                
  Histologic grade        G1                 7                                        39                                       0.2814
  G2/G3                   40                 138                                                                               
  FIGO stage              I-II               7                                        90                                       \< 0.0001
  III-IV                  41                 96                                                                                
  Optimal debulking       No                 8                                        23                                       0.4332
  Yes                     40                 163                                                                               
  Malignant ascites       No                 12                                       98                                       \< 0.0001
  Yes                     36                 88                                                                                
  CA-125 (Unit/mL)                           48            1842.7 ± 3318.6            185           681.4 ± 1486.3             \< 0.0001
  Albumin (g/dL)                             48            3.3 ± 0.7                  186           4.2 ± 0.5                  \< 0.0001
  WBC (per µL)                               48            8876.5 ± 3551.9            186           7044.1 ± 2321.7            \< 0.0001
  ANC (per µL)                               48            7107.5 ± 3296.5            186           4732.6 ± 2089.9            \< 0.0001
  ALC (per µL)                               48            992.5 ± 446.8              186           1716.1 ± 663.6             \< 0.0001
  AMC (per µL)                               48            684.7 ± 311.8              186           401.2 ± 166.5              \< 0.0001
  Hemoglobin (g/dL)                          48            11.9 ± 1.8                 186           12.3 ± 1.5                 0.2128
  Platelet (× 10^3^/µL)                      48            337.7 ± 172.9              186           308.5 ± 102.2              0.1335
  NLR                                        48            8.3 ± 5.0                  186           3.2 ± 2.1                  \< 0.0001
  PLR                                        48            406.0 ± 322.6              186           205.4 ± 103.2              \< 0.0001

*P*-values for comparisons of mean differences in continuous variables were obtained using a *t*-test.

*P*-values for comparisons of categorical variables were obtained using the chi-squared test.

CA-125, cancer antigen 125; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio

###### 

Relationship of cancer- and host-related characteristics with progression-free survival in 234 patients with epithelial ovarian cancer

  Variable                                 Univariate                       Multivariate                       
  ---------------------------------------- -------------------- ----------- -------------- ------------------- --------
  Age (years) (≤62 vs. \>62)               2.32 (1.44, 3.72)    0.0005                     1.65 (1.02, 2.67)   0.0421
  Histology (serous vs. non-serous)                                                                            
  Histologic grade (G1 vs. G2/G3)                                                                              
  FIGO stage (I-II vs. III-IV)             5.17 (2.63, 10.17)   \< 0.0001                  3.32 (1.61, 6.85)   0.0012
  Optimal debulking (yes vs. no)           1.91 (1.08, 3.40)    0.0268                                         
  Malignant ascites (no vs. yes)           2.27 (1.34, 3.86)    0.0025                                         
  CA-125 (Unit/mL ) (≤110.1 vs. \>110.1)   4.48 (2.23, 8.99)    \< 0.0001                  2.28 (1.08, 4.81)   0.0313
  Albumin (g/dL) (≤3.4 vs. \>3.4)          0.47 (0.29, 0.76)    0.0023                                         
  WBC (per µL) (≤6400 vs. \>6400)                                                                              
  ANC (per µL) (≤5053.4 vs. \>5053.4)      1.92 (1.21, 3.06)    0.0061                                         
  ALC (per µL) (≤1142.0 vs. \>1142.0)      0.49 (0.31, 0.78)    0.0027                                         
  AMC (per µL) (≤327.0 vs. \>327.0)                                                                            
  Hemoglobin (g/dL) (≤12.0 vs. \>12.0)     0.49 (0.29, 0.84)    0.0099                                         
  Platelet (x 10^3^/µL) (≤277 vs. \>277)   1.75 (1.05, 2.93)    0.0338                                         
  NLR (≤5.03 vs. \>5.03)                   2.34 (1.45, 3.77)    0.0005                                         
  PLR (≤246.80 vs. \>246.80)               1.98 (1.24, 3.14)    0.0042                                         
  LMR (≤2.07 vs. \>2.07)                   0.40 (0.23, 0.69)    0.0012                                         

Hazard ratios were obtained using Cox\'s proportional hazard model.

HR, hazard ratio; CI, confidence interval; CA-125, cancer antigen 125; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio

###### 

Relationship of cancer- and host-related characteristics with overall survival in 234 patients with epithelial ovarian cancer

  Variable                                 Univariate                      Multivariate                       
  ---------------------------------------- ------------------- ----------- -------------- ------------------- --------
  Age (years) (≤62 vs. \>62)               2.74 (1.60, 4.70)   0.0002                     2.16 (1.24, 3.76)   0.0064
  Histology (serous vs. non-serous)                                                                           
  Histologic grade (G1 vs. G2/G3)                                                                             
  FIGO stage (I-II vs. III-IV)             4.56 (2.13, 9.78)   \< 0.0001                  3.36 (1.52, 7.47)   0.0029
  Optimal debulking (yes vs. no)           2.63 (1.43, 4.84)   0.0018                                         
  Malignant ascites (no vs. yes)           3.28 (1.64, 6.56)   \< 0.0001                                      
  CA-125 (Unit/mL ) (≤110.1 vs. \>110.1)   3.06 (1.50, 6.25)   0.0022                                         
  Albumin (g/dL) (≤3.9 vs. \>3.9)          0.45 (0.23, 0.69)   0.0012                                         
  WBC (per µL) (≤6400 vs. \>6400)                                                                             
  ANC (per µL) (≤4955.0 vs. \>4955.0)      2.01 (1.17, 3.44)   0.0121                                         
  ALC (per µL) (≤1350.0 vs. \>1350.0)      0.55 (0.32, 0.94)   0.0290                                         
  AMC (per µL) (≤327.0 vs. \>327.0)                                                                           
  Hemoglobin (g/dL) (≤12.0 vs. \>12.0)     0.49 (0.29, 0.84)   0.0099                                         
  Platelet (x 10^3^/µL) (≤282 vs. \>282)   1.98 (1.08, 3.63)   0.0285                                         
  NLR (≤4.28 vs. \>4.28)                   2.01 (1.18, 3.43)   0.0103                                         
  PLR (≤292.50 vs. \>292.50)               2.70 (1.58, 4.60)   0.0003                                         
  LMR (≤2.07 vs. \>2.07)                   0.40 (0.23, 0.68)   0.0008                     0.53 (0.30, 0.94)   0.0293

Hazard ratios were calculated using Cox\'s proportional hazard model.

HR, hazard ratio; CI, confidence interval; CA-125, cancer antigen 125; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; LMR, lymphocyte-monocyte ratio

[^1]: \*These authors equally contributed to this work.

[^2]: Competing Interests: The authors have declared that no competing interest exists.
